Inactivation of the BRCA1 gene has been found to confer susceptibility to early-onset familial breast and ovarian cancers. BRCA1 regulates DNA repair, chromatin remodeling and affects gene transcription. Transforming growth factor-b (TGFb) is a potent regulator of growth, apoptosis and invasiveness of tumor cells, including breast cancer cells. Here we show that Smad3 which is a component of the TGFb signaling pathway, forms a complex with BRCA1 in vitro and in vivo. The interaction is mediated by the MH1 domain of Smad3 and the Cterminal part of BRCA1. We observed a co-localization of Smad3 and BRCA1 in nuclear complexes. We also found that TGFb1/Smad3 counteracted BRCA1-dependent repair of DNA double-strand breaks in human breast epithelial cells, as evaluated by BRCA1 nuclear foci formation, single-cell gel electrophoresis and cell survival assays. Thus, TGFb1/Smad3 suppresses BRCA1-dependent DNA repair in response to a DNA damaging agent.
Introduction
Inefficient repair of DNA lesions promotes cell transformation, and inactivation of genes coding for components of the DNA repair machinery therefore promotes tumorigenesis (Kinzler and Vogelstein, 1997) . Brca1 was found as a tumor susceptibility gene in a subset of hereditary breast and ovarian cancers. BRCA1 regulates DNA repair, transcription and chromatin remodeling through interactions with proteins involved in DNA lesion repair (Rad50, Rad51, BRCA2), cell cycle regulation (pRb, c-Myc) , cell checkpoint function (p53), degradation by ubiquitylation (BARD1), and transcriptional regulation (HDAC1, HDAC2, RNA helicase A, RNA polymerase II) (Wang et al., 2000; Venkitaraman, 2002) .
Smad proteins are mediators of the effect of transforming growth factor-b (TGFb) on expression of genes controlling proliferation and apoptosis of cells (de Caestecker et al., 2000; Derynck et al., 2001; Souchelnytskyi, 2002) . TGFb binds to specific receptors with intrinsic serine/threonine kinase activity; upon ligand binding, a heterotetrameric complex of two type I and two type II receptors is formed, in which receptor kinases are activated and phosphorylate Smad3 and Smad2. Receptor-phosphorylated Smads form complexes with the common mediator Smad4, which translocate into the nucleus and regulate gene transcription (Derynck and Zhang, 2003; Siegel and Massague, 2003) . Mutations or functional inactivation of Smad2, Smad3 and Smad4 have been observed in leukemias, as well as in colorectal, breast and pancreatic cancers. Restoration of Smad activities in tumor cells with mutated Smads led to inhibition of the tumorigenic properties of cells (de Caestecker et al., 2000; Derynck et al., 2001; Souchelnytskyi, 2002; Siegel and Massague, 2003) . Ablation of the Smad3 gene in mice has been reported to result in an enhanced colorectal tumorigenesis, albeit the tumorigenic effect appears to depend on the mouse strain used (Zhu et al., 1998) .
Functional interaction between various tumor suppressors and oncogenes has been observed in tumorigenesis. Thus, oncogenic v-Ras was shown to counteract the tumor suppressor effect of Smad2 in a model of human breast tumorigenesis (Kretzschmar et al., 1999; Mulder, 2000) . Compound APC/Smad4 mice developed colorectal cancer (Takaku et al., 1998) , suggesting an importance of simultaneous inactivation of these two tumor suppressors. Tumor promoter phorbol esters, via an induction of PKC-dependent phosphorylation of Smad3, inhibited TGFb-dependent contact inhibition and apoptosis of cells (Yakymovych et al., 2001) . Here, we describe a functional cross-talk between two types of regulators of tumor growth, that is, BRCA1, which contributes to maintenance of genome stability, and Smad3, which is involved in TGFb-dependent regulation of cell proliferation, apoptosis, migration and differentiation. We describe opposite effects of TGFb1/Smad3 and BRCA1 on repair of DNA damage and sensitivity of cells to DNA damaging drug.
Material and methods

Cells and reagents
293 T, MCF7, HCC1937 and A549 cells were obtained from ATCC (Manassas, VA, USA), and were cultured in DMEM with 10% FBS. His-BRCA1 and Flag-BRCA1 constructs were obtained from Toru Ouchi (Ouchi et al., 1998) . GST-Smad3, full-length and deletion mutants, GST-Smad2, GST-Smad4, GST and myc-Smad3 in pcDNA3 vector were described by Yakymovych et al. (2001) . A construct of Smad3 lacking MH1 domain in pMEP4 vector was used for stable transfection of MCF7 cells. GST constructs of BRCA1 were obtained from Dou Liu and Stephen Elledge (Paull et al., 2001) . Adenoviruses encoding BRCA1, LacZ and myc-Smad3 were obtained from Didier Marot and Kohei Miyazono, respectively. HA-p53-pcDNA3 was obtained from Johan Ericsson. CAGA(12)luc, pGluc and Gal4-TK-luc reporter plasmids were described previously (Dennler et al., 1998; Paull et al., 2001; Pulaski et al., 2001) . , anti-BRCA1 (C-20 and H-100) antibodies were from Santa Cruz (USA).
Immunoprecipitation and immunoblotting
Immunoprecipitation and immunoblotting were performed as described previously (Yakymovych et al., 2001; Kanamoto et al., 2002) . In vitro translation of Smad3 and control bgalactosidase proteins were performed using Promega TnT Quick Coupled transcription/translation system kit (Promega, USA) with addition of 35 S-protein labeling mixture (ProMix, Amersham Bioschiences, Uppsala, Sweden). In vitro synthesized proteins were analysed by SDS-PAGE, and were visualized after exposure in a phosphorimager Fuji FLA2000 (Fuji, Tokyo, Japan).
GST pull-down assay
At 24 h after 293T cells were transfected with control empty vector or Flag-BRCA1, cells were treated with 5 ng/ml TGFb1 for 24 h. Then, cells were lysed, and lysates were mixed with GST or GST-Smad3 fusion proteins at 41C for 2 h, and collected on Glutathione-Sepharose. After washing, samples were subjected to SDS gel electrophoresis. Proteins were transferred onto a nitrocellulose membrane (Hybond-C, Amersham Life Science, UK), and immunoblotted with antiFlag (M2, Kodak) or anti-myc (9E10, Santa Cruz, USA) antibody, as described earlier (Yakymovych et al., 2001; Kanamoto et al., 2002) .
Reporter assays
Reporter assays with CAGA(12)-luc, Gal4-TK-Luc and pGluc reporters were performed as described earlier (Yakymovych et al., 2001; Preobrazhenska et al., 2002) .
Infections of cells
MCF7 cells were infected at 100 moi (multiplication of infection) for Smad3 and LacZ, and at 40 moi for BRCA1 adenoviruses. Cells were used for experiments after 18-24 h after infection.
Imunohistochemistry
Immunohistochemical staining with anti-BRCA1 and antiSmad3 antibodies was performed essentially as described by Kanamoto et al. (2002) . MCF7 cells, infected as indicated, were treated with TGFb1 (5 ng/ml) for 24 h, and then with mitomycin C (MMC) (2.5 mg/ml) for 1 h. Cells containing more than five BRCA1 complexes in the nucleus were scored as positive for BRCA1 nuclear complex formation. Totally, at least 100 cells were examined, and the percentage of positive cells calculated. For BRCA1 and Smad3 co-localization study, the primary antibodies were visualized by FITC-or TRITCconjugated secondary antibodies for BRCA1 and Smad3, respectively. Expression of BRCA1 and Smad3 in infected cells was evaluated by immunoblotting of whole-cell lysates with antibodies recognizing epitopes also in endogenous proteins. Efficiency of infection was estimated to be higher than 90% of cells. Efficiency of transient transfections was evaluated also by co-transfection of a GFP-expressing plasmid. Co-transfection of GFP allowed estimation of the transient transfection Single-cell gel electrophoresis assay MCF7 cells were infected as indicated, and were treated for 24 h with TGFb1 (2.5 or 5 ng/ml) and then for 1 h with MMC (2.5 mg/ml). Single-cell gel electrophoresis was performed as described by Kanamoto et al. (2002) . Five different fields were photographed and the size of comet tail of at least 50 cells per experimental condition was measured.
Cell survival assay
Cell survival assay with MCF7 cells was performed as described by Kanamoto et al. (2002) . Cells were cultured for 10 days before counting foci. Foci containing more than 100 cells were scored as positive.
Results
Smad3 and BRCA1 form a complex
First, we explored whether Smad3 and BRCA1 form a complex in vitro. We found that Flag-BRCA1, which was expressed in cells, interacted with full-length Smad3 fused to GST, in a pull-down assay. This interaction is mediated by the MH1 domain of Smad3, as a GSTSmad3DMH2 construct, lacking the MH2 domain, interacted with Flag-BRCA1, while GST-Smad3DMH1, lacking the MH1 domain, did not ( Figure 1a ). We observed TGFb1-dependent interaction of Flag-BRCA1 with GST-Smad3DMH2, while less dependency on TGFb1 was observed for the full-length Smad3 construct fused to GST, that is, GST-Smad3 (Figure 1a) . This suggests that TGFb1 may affect the ability of BRCA1 to interact with Smad3, though the mechanism of this effect remains to be investigated. Flag-BRCA1 also interacted with GST-Smad4 and GST-Smad2 (data not shown; supplementary Figure A) . To identify the interacting domain in BRCA1, we performed a pulldown assay with GST-fusion constructs expressing various parts of BRCA1. We found an interaction of myc-Smad3 with the C-terminal part of BRCA1, aminoacid residues 1501-1861, which contains two C-terminal transcription activation domains (BRCT; Figure 1b) . The interaction between myc-Smad3 and the BRCA1 fragment was promoted by treatment of myc-Smad3-transfected cells with TGFb1, suggesting that activation of Smad3 may enhance the interaction with BRCA1 (Figure 1b) . Thus, BRCA1 and Smad3 form a complex in vitro; the interaction is mediated by the MH1 domain of Smad3, and the C-terminal part of BRCA1 containing the BRCT domains.
To explore whether BRCA1 and Smad3 interact in vivo, we first performed a co-immunoprecipitation assay of Flag-BRCA1 and myc-Smad3 co-expressed in 293 T cells. We found that Flag-BRCA1 co-precipitated with myc-Smad3 in the presence of constitutively active type I TGFb receptor (TbR-I) and treatment with the ligand; TbR-I was transfected to enhance TGFb signaling ( Figure 1c ). We also tested whether endogenous BRCA1 and Smad3 form a complex in MCF-7 human breast carcinoma cells. Cells treated or not with TGFb1 were subjected to immunoprecipitation with an antibody against endogenous Smad3, followed by immunoblotting with an antibody against endogenous BRCA1 (Figure 1d ). We detected BRCA1-specific bands in Smad3-immunoprecipitates; these bands were not observed in immunoprecipitates of non-immune serum (Figure 1d ), and they were significantly weaker when the anti-Smad3 immunoprecipitation was performed in the presence of specific blocking peptides (data not shown, supplementary Figure B) . We observed an increase in the amount of BRCA1 co-precipitated with Smad3 after treatment of cells with TGFb1, which is in agreement with the results of the GST pull-down assay with deletion constructs of BRCA1 and the TGFb1/ TbR-I-dependent complex formation in 293 T cells (Figure 1b, c) .
To explore Smad3 and BRCA1 interaction further, we performed a pull-down assay with a GST-fusion protein of the C-terminal part of BRCA1, amino-acid residues 1501-1861, and Smad3 constructs translated in vitro (Figure 1e ). It is unlikely that other proteins may mediate the interaction between Smad3 and BRCA1, as GST-BRCA1-1501-1861 protein was purified, and the preparation of in vitro translated Smad3 only contains proteins optimized for in vitro translation. We found that in vitro translated full-length Smad3 and Smad3DMH2, but not Smad3DMH1, associated with GST-BRCA1(1501 -1861 . No interaction of Smad3 constructs with only GST was observed, neither was any interaction detected of any of the GST constructs with in vitro translated control b-galactosidase protein.
These data suggest that the interaction between in vitro translated Smad3 and BRCA1 is mediated by the MH1 domain of Smad3. This is in agreement with results of the GST pull-down experiments with proteins expressed in cells (Figure 1a) . Thus, taken together our results show that Smad3 forms a complex with BRCA1 in vivo and in vitro.
Smad3 and BRCA1 cooperate in regulation of transcription
We then evaluated whether BRCA1 affects Smad3-dependent transcriptional regulation. We used the CAGA(12)luc reporter, which is specifically activated by the direct binding of Smad3 to the promoter of the reporter (Dennler et al., 1998) . We observed TGFb1/ TbR-I-dependent induction of the reporter in the presence of Smad3, and that transfection of full-length BRCA1 alone affected luciferase expression marginally (Figure 2a ). Co-transfection of full-length BRCA1 with Smad3 resulted in a strong induction of the reporter. We observed that co-transfection with Smad3 of a mutant of BRCA1 containing the C-terminal residues 1501-1861, which bind Smad3, resulted in weaker induction of the luciferase activity, as compared to the effect of transfection of Smad3 alone (Figure 2a ). Co-transfection of a mutant of BRCA1 containing the N-terminal residues 1-1500, which does not bind Smad3, also did not result in a significant increase of the luciferase activity (Figure 2a) . Thus, cooperation between Smad3 and BRCA1 in activation of the CAGA(12)-luc reporter requires an intact BRCA1.
The cooperation between BRCA1 and Smad3 did not require a direct DNA binding of Smad3 via the MH1 domain, as the transcriptional activity of Smad3 fused to the Gal4-DNA binding domain also was enhanced by the co-transfection of BRCA1 (Figure 2b ). In this assay, Smad3 bound to DNA indirectly via the Gal4-DNA binding domain and not via the MH1 domain. The cooperative effect of BRCA1 on the Smad3-dependent transcription is not reciprocal, as co-transfection of Smad3 did not affect the BRCA1-dependent enhancement of luciferase expression from a p53-responsive pGluc reporter (Figure 2c ).
Smad3 inhibits formation of BRCA1 nuclear complexes
A major mechanism of tumor suppression by BRCA1 is thought to be due to BRCA1-dependent repair of DNA lesions, with an essential role in repair of double-strand breaks (DSB) by homologous recombination (Venkitaraman, 2002) . Upon challenging cells with DNAdamaging agents, BRCA1 form nuclear complexes with other proteins, for example, Rad51 and Rad50/Mer1. These complexes execute DNA repair, and BRCA1 can be detected in these complexes as distinct foci by an immunofluorescence assay ( Figure 3a) ; appearance of nuclear foci correlates to the efficiency of BRCA1-dependent DNA repair (Scully et al., 1997) . To achieve high efficiency of protein expression, MCF7 cells were infected with Smad3 and BRCA1 adenoviruses. Smad3 and BRCA1 proteins expressed upon virus infection formed a complex in a similar way as transiently expressed proteins (Figure 1; Supplementary Figure C) . To induce DNA DSB, MCF7 cells were pretreated with MMC, then cells were cultured for 12 h to allow DNA repair, including formation of BRCA1-containing nuclear complexes. As expected, treatment of cells with MMC induced formation of BRCA1 complexes in virusinfected cells ( Figure 3a) ; these complexes may be considered as DNA repair-related. BRCA1 staining in nucleus in the absence of DNA damage may be due to BRCA1 involvement in transcriptional regulation. We found that formation of MMC-induced BRCA1 complexes decreased upon TGFb1 treatment of noninfected cells, while LacZ virus infection interfered with the (12)-luc reporter. 293T cells were transfected with CA-GA(12)luc luciferase reporter plasmid, and with myc-Smad3, full length BRCA1 (BRCA1-FL), deletion mutants of BRCA1 containing the C-terminal residues 1501-1861 (BRCA1-C-term), and containing the N-terminal residues 1-1500 (BRCA1-N-term), and constitutively active TbR-I (T204D mutant), alone or in combinations, as indicated. Cells were treated or not with TGFb1 (5 ng/ml) for 24 h, and luciferase activity was measured. (b) BRCA1 enhances Gal4-Smad3 transcriptional activity. A549 cells were transfected with Gal4-TK-luc luciferase reporter plasmid, and Gal4-Smad3 and full-length His-BRCA1 alone or in combinations, as indicated. Cells were treated with TGFb1 as in panel (a), and luciferase activity was measured. (c) Smad3 does not affect BRCA1-dependent induction of pGluc reporter. A549 cells were transfected with p53-responsive luciferase reporter plasmid pGluc, and with HA-p53, His-BRCA1 and myc-Smad3, as indicated. Cells were treated with TGFb1 or not, as in panel (a), and luciferase activity was measured. For normalization, cells in all described experiments were co-transfected with a LacZ containing plasmid, and bgalactosidase activity was measured. To explore whether Smad3 is present in BRCA1 nuclear complexes, we double-stained MCF7 cells expressing both Smad3 and BRCA1, with antibodies specific to Smad3 and to BRCA1 (Figure 4) . The respective antibodies were detected with FITC-conjugated secondary antibodies for BRCA1 detection, and TRITC-conjugated secondary antibodies for Smad3 detection. We observed formation of BRCA1 nuclear complexes after treatment of cells with MMC, and nuclear accumulation of Smad3 after TGFb1 treatment. Merged images showed that the part of Smad3 and BRCA1 co-localized in nuclear complexes of cells treated with MMC and TGFb1 (Figure 4) . The colocalization of Smad3 and BRCA1 in these complexes Figure 4 Co-localization of Smad3 and BRCA1 in nuclear complexes. MCF7 cells infected with myc-Smad3 and BRCA1 viruses were treated with MMC (2.5 mg/ml) and TGFb1 (5 ng/ml) or were left nontreated, as indicated. Smad3 and BRCA1 were visualized by staining of cells with specific antibodies and with TRITC-and FITC-conjugated secondary antibodies, as indicated. Merged images showed partial co-localization of Smad3 and BRCA1 in nuclei of MMC-and TGFb1-treated cells. Enlarged views of single cells with merged images are shown in right column of panels. Open arrowheads indicate BRCA1 nuclear complexes, and countered arrowheads indicate nuclear accumulation of Smad3. Arrows show complexes containing both myc-Smad3 and BRCA1. Pictures of representative experiment out of five performed, are shown suggests that the TGFb1/Smad3-dependent counteraction of BRCA1-dependent complex formation may be due to the interaction between Smad3 and BRCA1 (Figure 1 ).
Smad3 inhibits BRCA1-dependent repair of DNA damage and cell survival
We also evaluated the efficiency of repair of damaged genomic DNA by single-cell gel electrophoresis. In this assay, nonefficiently repaired DNA migrates faster and forms longer 'comet tails' than the DNA with repaired breaks (Figure 5a, inset) . Treatment of LacZ-infected cells with MMC led to increase of comet tail length (Figure 5a) , as a consequence of MMC-induced DNA damage. Overexpression of Smad3 increased significantly the length of the tails in cells treated with both TGFb1 and MMC. Infection of cells with BRCA1 virus resulted in strong decrease of residual DNA fragmentation; this effect is expected, as BRCA1 increases the efficiency of DNA damage repair. Co-expression of Smad3 and BRCA1 resulted in generation of comets with shorter length of DNA tails, as compared to cells expressing Smad3 only, but longer than those of BRCA1-infected cells (Figure 5a Figure D) . The comet assay with HCC1937 cells that express inactive truncated BRCA1 protein showed no effect of TGFb1 and Smad3 on the length of comet tails (Supplementary Figure D) . Restoration of BRCA1 activity in BRCA1-deficient HCC1937 cells resulted in decrease of the DNA fragmentation. Thus, MMCinduced fragmentation of DNA in MCF7 cells increased upon overexpression of Smad3 and treatment with TGFb1, while BRCA1 decreased the level of DNA fragmentation due to efficient damage repair.
To further investigate the effect of BRCA1 and TGFb1/Smad3 on DNA repair, a cell survival assay was performed. In this assay, DNA breaks are introduced by MMC treatment, and cell survival correlates with ability of the cells to repair the DNA damage. Cell survival assay evaluates a long-term effect of DNA damage, and may reflect not only efficiency of DNA damage repair itself, but also DNA damage induced pro-apoptotic and growth-inhibitory signaling. Thus, foci formation assay evaluates complex regulatory mechanisms involved in cell survival. We observed that treatment of cells with TGFb1 decreased formation of cellular foci, as compared to nontreated cells (data not shown). This could reflect TGFb1 effect on DNA repair, as well as the effect on cell proliferation and apoptosis. As we were interested in exploration of cell survival upon DNA damage repair, we studied effect of TGFb1, Smad3 and BRCA1 on survival of cells that were treated with MMC (Figure 5b ). Overexpression of Smad3 decreased survival of cells, as compared to LacZinfected cells; pretreatment of Smad3-infected cells with MMC and TGFb1 led to further strong inhibition of cell survival. BRCA1-infected cells showed highest survival rate upon treatment of cells with MMC alone or in combination with TGFb1. Co-expression of Smad3 and BRCA1 resulted in decrease of the survival rate, as compared to cells infected with BRCA1 virus alone (Figure 5b) . Thus, TGFb1/Smad3 counteracted BRCA1-dependent cell survival.
Taken together, Smad3 expression and TGFb1 stimulation counteracted the effect of BRCA1 on DNA repair, as analysed by three different assays, that is, formation of the BRCA1 complexes in nucleus, rate of DNA DSB repair, as determined by single-cell electrophoresis, and an overall effect on cell recovery after DNA damage. The combination of three types of assays strengthens the notion that Smad3 and BRCA1 have opposite roles in maintenance of genome integrity (Figures 2-5 ).
Discussion
Our study describes for the first time an interaction between two important regulators of tumorigenesis, that is, BRCA1 and TGFb/Smad3. We provide evidence that TGFb1/Smad3 counteracts the BRCA1-dependent repair of DNA damage, but cooperates with BRCA1 in activation of transcription. Our study also provides an insight into possible mechanisms of growth factordependent modulation of tumor cell sensitivity to chemotherapy. The TGFb1/Smad3-dependent decrease of DNA repair efficiency described here, may result in sustained DNA damage upon treatment with MMC, triggering cell death and increasing the cytotoxic efficiency of the drug on tumor cells. Such a TGFbdependent increase of the cytotoxic efficiency of drugs may contribute to the efficiency of patient treatment. This mechanism, together with other effects of TGFb, such as growth inhibition, can explain the fact that intact TGFb/Smad signaling in tumor cells correlates with longer survival of patients with breast cancer (Muray et al., 1993; Xie et al., 2002) , colorectal (Watanabe et al., 2001; Boulay et al., 2002) and advanced gastric (Xiangming et al., 2001 ) cancers, renal cell carcinoma (Miyajima et al., 2003) and ovarian cancer (Volodko et al., unpublished data) .
An increased chromosomal instability was found in pancreatic cancer cells, which express high levels of TGFb2 (Schmied et al., 2000) . This suggests that at a low rate of DNA damage, TGFb may increase the incidence of chromosomal instability, rather than increasing the incidence of cell death. Following the pilot study of BRCA1 expression and phosphorylation of Smad2 in breast cancer cells (Xie et al., 2002) and our case-studies that show a positive correlation between Smad3 expression in breast and ovarian cancer cells and survival period of patients (Volodko et al., unpublished data), it will be important to investigate a larger cohort of patients with a long-term follow-up.
The effect of TGFb on proteins involved in repair of DNA damage should be evaluated in the context of other activities of TGFb. Consequences of DNA damage, for example, cell death or accumulation of mutations, may depend on the rate of cell proliferation and sensitivity to apoptosis (Glick et al., 1999 ). TGFb's ability to inhibit cell proliferation may protect against appearance of mutations (Glick et al., 1999; Siegel and Massague, 2003) . The requirement of TGFb1 for p53 activation and for radiation-induced apoptosis in response to ionizing radiation showed an involvement of TGFb1 in signaling induced by DNA damage (Ewan et al., 2002) . It is important to further explore relation between TGFb-dependent regulation of DNA repair and cell cycle, as well as p53 and BRCA1 activities, to evaluate contribution of these regulatory processes in human breast tumorigenesis.
This study and our previous finding that expression of Rad51 protein is downregulated by TGFb1 , depict a novel pathway in TGFb signaling directed to regulation of integrity of genomic DNA. Formation of a complex between Smad3 and BRCA2, and the effect of TGFb on the expression of Rag1 and ORC5T Preobrazhenska et al., 2002; Lomnytska et al., 2004) , suggest that TGFb regulates proteins affecting genome integrity. The data described here, identifies BRCA1 as a binding partner of Smad3, and shows that TGFb1/Smad3 inhibits BRCA1-dependent repair of DNA damage. Thus, our demonstration of a cross-talk between Smad3 and BRCA1 represents a potentially important molecular mechanism during human breast tumorigenesis, and may contribute to understanding of the differential sensitivity of tumors to chemotherapy.
